Grant: Canada Postdoctoral Research Award (CPRA) program
McGill University
$140,000.00
Optimizing tau-PET staging across atlases and tracers to improve early Alzheimer's disease detection
EF 2025-26
Résumé
Alzheimer's disease begins many years before symptoms appear. One of the earliest brain changes is the buildup of a protein called tau in memory-related regions. Brain scans using positron emission tomography (PET) can measure tau, but the current methods for interpreting these scans are not sensitive enough in the earliest stages of the disease. This limits their use for diagnosis and for selecting the right participants in clinical trials of new treatments.
This project will improve how tau-PET scans are analyzed. First, we will refine the brain maps (atlases) used to identify where tau appears, ensuring that they better account for differences in brain anatomy and age-related shrinkage. Second, we will improve the measurement of tau in the hippocampus, a key memory structure often affected early in Alzheimer's. Third, we will test how different reference groups (healthy young adults versus healthy older adults) influence the thresholds used to define "abnormal" tau across several tracers. Finally, we will develop a new method that stages tau accumulation in each person's own brain space, and link this with memory performance to increase accuracy.
Together, these steps will make tau-PET staging a more reliable and interpretable tool. Importantly, this approach is consistent with the recent Alzheimer's Association framework, which proposes a practical staging system for tau pathology (from tau in the medial temporal lobe to more widespread cortical involvement). By refining these methods and validating them across multiple large international cohorts, this project will help identify Alzheimer's disease earlier, improve patient selection for clinical trials, and support the development of effective treatments.
Programme
Canada Postdoctoral Research Award (CPRA) program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
536829
Name
Aumont Étienne
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Aging
Theme2
Biomedical
Prcname2
Canada Postdoctoral Research Award - A
Projecttitle
Optimizing tau-PET staging across atlases and tracers to improve early Alzheimer's disease detection
Programtype2
Fellowship Programs
Orgnameinp2
McGill University
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Canada Postdoctoral Research Award (CPRA) program
Keyworddelim
Alzheimer'S Disease; Biomarker; Brain Imaging; Cognitive Decline; Early Detection; Tau Pathology
Abstract
Alzheimer's disease begins many years before symptoms appear. One of the earliest brain changes is the buildup of a protein called tau in memory-related regions. Brain scans using positron emission tomography (PET) can measure tau, but the current methods for interpreting these scans are not sensitive enough in the earliest stages of the disease. This limits their use for diagnosis and for selecting the right participants in clinical trials of new treatments.
This project will improve how tau-PET scans are analyzed. First, we will refine the brain maps (atlases) used to identify where tau appears, ensuring that they better account for differences in brain anatomy and age-related shrinkage. Second, we will improve the measurement of tau in the hippocampus, a key memory structure often affected early in Alzheimer's. Third, we will test how different reference groups (healthy young adults versus healthy older adults) influence the thresholds used to define "abnormal" tau across several tracers. Finally, we will develop a new method that stages tau accumulation in each person's own brain space, and link this with memory performance to increase accuracy.
Together, these steps will make tau-PET staging a more reliable and interpretable tool. Importantly, this approach is consistent with the recent Alzheimer's Association framework, which proposes a practical staging system for tau pathology (from tau in the medial temporal lobe to more widespread cortical involvement). By refining these methods and validating them across multiple large international cohorts, this project will help identify Alzheimer's disease earlier, improve patient selection for clinical trials, and support the development of effective treatments.
Competitiondate
202509
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Aumont, Étienne
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~